InvestWiserBiosergen AS
BIOSGN · Nasdaq Stockholm · Healthcare
0.51SEK
+1.0%last day
Price as of 2 October 2026
Performance
1 month
−63.1%
1 year
−99.0%
3 years, per year
−81.6%
5 years, per year
−74.5%
Largest fall, 3 years
−99.5%
Below the peak now
−99.9%
Volatility, 1 year
82.4%
Return with dividends reinvested.
Key figures
P/E
negative earnings
P/B
1.6
Dividend yield
0.0%
Return on equity
−347.0%
Net margin
–
Market value
0 m USD
Quality, value and trend
Where Biosergen stands against every Nordic stock today. 100 is best.
32
Profitability and a sound balance sheet over time. Better than 32% of Nordic stocks.
17
The price measured against earnings, assets and cash flow. Better than 17% of Nordic stocks.
0
The price development over the past year. Better than 0% of Nordic stocks.
3
Quality, value and trend together. Better than 3% of Nordic stocks.
About Biosergen
Biosergen AS is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 1 employees.
Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis